Sartorius
Last month, this company launched the ambr 250 high-throughput (ht) perfusion (photo), a new automated parallel bioreactor system. It has been specially designed for rapid cell-culture-perfusion process development to optimize production of therapeutic antibodies. The ambr 250ht perfusion system was developed in collaboration with major biopharmaceutical companies. It combines 12 or 24 single-use perfusion mini bioreactors (100–250 mL working volume) with associated single-use perfusion components, all controlled by one automated workstation. The combination of this multi-parallel processing capacity and fully single-use perfusion vessel enables scientists to perform more perfusion culture experiments in a fraction of the time and cost of using traditional perfusion-enabled benchtop bioreactors. This new innovation supports a range of hollow-fiber perfusion applications, enabling design of experiments (DoE) studies for high-cell-density process development in a quality by design (QbD) approach. — Sartorius Stedim Biotech, Göttingen, Germany